Disease: Cardiomyopathy due to anthracyclines
- <em>RBL2</em> Regulates Cardiac Sensitivity to Anthracycline Chemotherapy
- A combination of isoliquiritigenin with Artemisia argyi and Ohwia caudata water extracts attenuates oxidative stress, inflammation, and apoptosis by modulating Nrf2/Ho-1 signaling pathways in SD rats with doxorubicin-induced acute cardiotoxicity
- ACEI/ARB and beta-blocker therapies for preventing cardiotoxicity of antineoplastic agents in breast cancer: a systematic review and meta-analysis
- Adverse Cardiovascular Events Associated With Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Metastatic Breast Cancer
- AKT2 deficiency alleviates doxorubicin-induced cardiac injury via alleviating oxidative stress in cardiomyocytes
- Alleviation of doxorubicin-induced cardiotoxicity in rat by mesenchymal stem cells and olive leaf extract via MAPK/ TNF-α pathway: Preclinical, experimental and bioinformatics enrichment study
- Altered Peripheral Blood Gene Expression in Childhood Cancer Survivors With Anthracycline-Induced Cardiomyopathy - A COG-ALTE03N1 Report
- An In Vitro Examination of Whether Kratom Extracts Enhance the Cytotoxicity of Low-Dose Doxorubicin against A549 Human Lung Cancer Cells
- An Intraperitoneal Injection Technique in Adult Zebrafish that Minimizes Body Damage and Associated Mortality
- Angiotensin IV ameliorates doxorubicin-induced cardiotoxicity by increasing glutathione peroxidase 4 and alleviating ferroptosis
- Anthracycline induced left ventricular dysfunction in AML: A focus on the molecularly defined future of cardio-oncology
- Anthracycline Toxicity
- Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directions
- Artificial intelligence-enhanced risk stratification of cancer therapeutics-related cardiac dysfunction using electrocardiographic images
- Azilsartan improves doxorubicin-induced cardiotoxicity via inhibiting oxidative stress, proinflammatory pathway, and apoptosis
- Baicalin-peptide supramolecular self-assembled nanofibers effectively inhibit ferroptosis and attenuate doxorubicin-induced cardiotoxicity
- Beyond Expectations: A Case of Doxorubicin-Induced Cardiomyopathy at a Remarkably Low Cumulative Dose
- Bibliometric and visual analysis of doxorubicin-induced cardiotoxicity
- Bioinformatics and experimental studies jointly reveal that Sacubitril Valsartan improves myocardial oxidative stress and inflammation by regulating the MAPK signaling pathway to treat chemotherapy related cardiotoxicity
- Cardiac miRNA expression during the development of chronic anthracycline-induced cardiomyopathy using an experimental rabbit model
- Cardio-oncology for Pediatric and Adolescent/Young Adult Patients
- Cardioprotection in Patients at High Risk of Anthracycline-Induced Cardiotoxicity: <em>JACC: CardioOncology</em> Primer
- Cationic Vitamin E-TPGS Mixed Micelles of Berberine to Neutralize Doxorubicin-Induced Cardiotoxicity via Amelioration of Mitochondrial Dysfunction and Impeding Apoptosis
- Checkpoint inhibitor myocarditis with preceding immunosuppression and tolerance of sequential anthracycline therapy
- Chemotherapy in Pregnancy: Assessing the Safety of Adriamycin Administration in Pregnancy Complicated by Breast Cancer
- Chemotherapy induced right ventricular cardiomyopathy; a systematic review and meta-analysis
- COX5A Alleviates Doxorubicin-Induced Cardiotoxicity by Suppressing Oxidative Stress, Mitochondrial Dysfunction and Cardiomyocyte Apoptosis
- Design, Synthesis, and In Vivo Evaluation of Isosteviol Derivatives as New SIRT3 Activators with Highly Potent Cardioprotective Effects
- Desmosomes in Cell Fate Determination: From Cardiogenesis to Cardiomyopathy
- Development of Preventive Methods for Drug-induced Cardiotoxicity Using a Large-scale Medical Information Database
- Doxorubicin-induced cardiomyopathy is mitigated by empagliflozin via the modulation of endoplasmic reticulum stress pathways
- Doxorubicin-Induced Cardiomyopathy: A Preliminary Study on the Cardioprotective Benefits of 7-Hydroxyflavanone
- Doxorubicin, doxorubicinol, cardiotoxicity, breast cancer, volumetric absorptive microsampling, LC-MS/MS
- Dynamin-Related Protein 1 Binding Partners MiD49 and MiD51 Increased Mitochondrial Fission In Vitro and Atherosclerosis in High-Fat-Diet-Fed ApoE<sup>-/-</sup> Mice
- Early use of intrapartum intra-aortic balloon pump support for haemodynamic stabilization of peripartum and anthracycline-induced cardiomyopathy: a case report
- Effects of Doxorubicin on Extracellular Matrix Regulation in Primary Cardiac Fibroblasts from Mice
- Effects of N-acetyl-L-cysteine against apical periodontitis in rats with adriamycin-induced cardiomyopathy and nephropathy
- Efficacy and safety of cardiac resynchronization therapy in chemotherapy-induced cardiomyopathy: A systematic review
- Endoplasmic Reticulum Selective Autophagy Alleviates Anthracycline-Induced Cardiotoxicity
- EP1 activation inhibits doxorubicin-cardiomyocyte ferroptosis via Nrf2
- EPAC1 inhibition protects the heart from doxorubicin-induced toxicity
- ER-Specific Autophagy or ER-Phagy in Cardiac Myocytes Protects the Heart Against Doxorubicin-Induced Cardiotoxicity
- Euphorbia grantii Oliv. standardized extract and its fraction ameliorate doxorubicin-induced cardiomyopathy in Ehrlich carcinoma bearing mice
- Evaluation of cardiotoxicity of anthracycline-containing chemotherapy regimens in patients with bone and soft tissue sarcomas: A study of the FDA adverse event reporting system joint single-center real-world experience
- Exosomal miR-9-5p derived from iPSC-MSCs ameliorates doxorubicin-induced cardiomyopathy by inhibiting cardiomyocyte senescence
- Exploration of Key Immune-Related Transcriptomes Associated with Doxorubicin-Induced Cardiotoxicity in Patients with Breast Cancer
- Features of trastuzumab-related cardiac dysfunction: deformation analysis outside left ventricular global longitudinal strain
- Galectin-3 contributes to acute cardiac dysfunction and toxicity by increasing oxidative stress and fibrosis in doxorubicin-treated mice
- Gene-Level Analysis of Anthracycline-Induced Cardiomyopathy in Cancer Survivors: A Report From COG-ALTE03N1, BMTSS, and CCSS
- Genetic predisposition in chemotherapy-induced cardiomyopathy in a 65-year-old female with metastatic breast cancer
- Genetic Susceptibility for Anthracycline-Induced Cardiomyopathy: Novel Insights by Combining SNPs
- Genetic Testing in Evaluating Risk of Anthracycline Cardiomyopathy: Are We There Yet?
- Guidelines for Standardization of Pediatric Anthracycline Cardiomyopathy Echocardiogram Surveillance-A Call for Harmonization in the Field to Enhance Research in the Cancer Survivor Population
- Haptoglobin Gene Expression and Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors: A COG-ALTE03N1 Report
- Heart transplantation in patients with anthracycline-induced cardiomyopathy
- How I Treat: long-term survivors of childhood acute leukemia
- Hsa-miR-223-3p participates in the process of anthracycline-induced cardiomyocyte damage by regulating NFIA gene
- Identification of novel hypermethylated or hypomethylated CpG sites and genes associated with anthracycline-induced cardiomyopathy
- Identifying critical genes and pathways of doxorubicin-induced cardiomyopathy via bioinformatics analysis
- Impact of the ESC Cardio-Oncology Guidelines Biomarker Criteria on Incidence of Cancer Therapy-Related Cardiac Dysfunction
- Improved Cardiomyopathy Risk Prediction Using Global Longitudinal Strain and N-Terminal-Pro-B-Type Natriuretic Peptide in Survivors of Childhood Cancer Exposed to Cardiotoxic Therapy
- Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemia
- Inhalation of acidic nanoparticles prevents doxorubicin cardiotoxicity through improvement of lysosomal function
- Inhibiting mir-34a-5p regulates doxorubicin-induced autophagy disorder and alleviates myocardial pyroptosis by targeting Sirt3-AMPK pathway
- Inhibition of CDK7 mitigates doxorubicin cardiotoxicity and enhances anticancer efficacy
- Inhibition of Cyp1a Protects Mice against Anthracycline Cardiomyopathy
- Initial Phase of Anthracycline Cardiotoxicity Involves Cardiac Fibroblasts Activation and Metabolic Switch
- Left Ventricular Longitudinal Strain Abnormalities in Childhood Exposure to Anthracycline Chemotherapy
- Long-term QT prolongation in monkeys after doxorubicin administration at doses similar to breast cancer therapy
- MST1 mediates doxorubicin-induced cardiomyopathy by SIRT3 downregulation
- Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial
- Myeloperoxidase is a critical mediator of anthracycline-induced cardiomyopathy
- NADPH oxidase 2 inhibitor GSK2795039 prevents doxorubicin-induced cardiac atrophy by attenuating cardiac sympathetic nerve terminal abnormalities and myocyte autophagy
- NADPH oxidase 2 mediates cardiac sympathetic denervation and myocyte autophagy, resulting in cardiac atrophy and dysfunction in doxorubicin-induced cardiomyopathy
- Nanomedicine alleviates doxorubicin-induced cardiotoxicity and enhances chemotherapy synergistic chemodynamic therapy
- Obesity Predisposes Anthracycline-Treated Survivors of Childhood and Adolescent Cancers to Subclinical Cardiac Dysfunction
- PARP-2 mediates cardiomyocyte aging and damage induced by doxorubicin through SIRT1 Inhibition
- Pharmacological activation of GPX4 ameliorates doxorubicin-induced cardiomyopathy
- Pharmacotherapy for Cancer Treatment-Related Cardiac Dysfunction and Heart Failure in Childhood Cancer Survivors
- PHB2 ameliorates Doxorubicin-induced cardiomyopathy through interaction with NDUFV2 and restoration of mitochondrial complex I function
- Poly (ADP-ribose) polymerase pathway inhibitor (Olaparib) upregulates SERCA2a expression and attenuates doxorubicin-induced cardiomyopathy in mice
- Predicting Left Ventricular Dysfunction in Childhood Cancer Survivors: In Search of the Echocardiography Holy Grail
- Presence and utility of electrocardiographic abnormalities in long-term childhood cancer survivors
- Prmt7 regulates the JAK/STAT/Socs3 signaling pathway in postmenopausal cardiomyopathy
- Protective effect of secretory APE1/Ref-1 on doxorubicin-induced cardiotoxicity via suppression of ROS and p53 pathway
- Pyridoxamine Attenuates Doxorubicin-Induced Cardiomyopathy without Affecting Its Antitumor Effect on Rat Mammary Tumor Cells
- Pyridoxamine Limits Cardiac Dysfunction in a Rat Model of Doxorubicin-Induced Cardiotoxicity
- Racial Disparity in Anthracycline-induced Cardiotoxicity in Breast Cancer Patients
- Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trial
- Screening of an FDA-approved compound library identifies apigenin for the treatment of myocardial injury
- Sex Differences in the Development of Anthracycline-Associated Heart Failure
- SIRT6 activates PPARα to improve doxorubicin-induced myocardial cell aging and damage
- Superiority of left heart deformation in early anthracycline-related cardiac dysfunction detection
- The Bach1/HO-1 pathway regulates oxidative stress and contributes to ferroptosis in doxorubicin-induced cardiomyopathy in H9c2 cells and mice
- The Lack of Synergy between Carvedilol and the Preventive Effect of Dexrazoxane in the Model of Chronic Anthracycline-Induced Cardiomyopathy
- The sGCa Vericiguat Exhibit Cardioprotective and Anti-Sarcopenic Effects through NLRP-3 Pathways: Potential Benefits for Anthracycline-Treated Cancer Patients
- Toxic Cardiomyopathy in a Young Patient Treated for Her2-Positive Early Breast Cancer: Case Report and Literature Review
- Use of Deep-Learning Assisted Assessment of Cardiac Parameters in Zebrafish to Discover Cyanidin Chloride as a Novel Keap1 Inhibitor Against Doxorubicin-Induced Cardiotoxicity
- USP36-mediated PARP1 deubiquitination in doxorubicin-induced cardiomyopathy
- Variants in structural cardiac genes in patients with cancer therapy-related cardiac dysfunction after anthracycline chemotherapy: a case control study